Other PARP inhibitors, such as talazoparib (Talzenna), veliparib, niraparib (Zejula), and rucaparib (Rubraca), are either under or have completed clinical trials to verify their role in treating breast cancer patients. The gene discussed is PARP1; the disease is breast cancer.